PF-Neostigmine Methylsulfate Injection, USP 3 mg/3 mL (1 mg/mL) vial, Rx Only, Nephron 503B Outso...

FDA Drug Recall #D-0065-2023 — Class II — November 10, 2022

Recall Summary

Recall Number D-0065-2023
Classification Class II — Moderate risk
Date Initiated November 10, 2022
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Nephron Sterile Compounding Center LLC
Location West Columbia, SC
Product Type Drugs
Quantity 56,220 vials

Product Description

PF-Neostigmine Methylsulfate Injection, USP 3 mg/3 mL (1 mg/mL) vial, Rx Only, Nephron 503B Outsourcing Facility 4500 12th Street Extension West Columbia, SC 29172, NDC 69374-932-33, UPC 3 69374-93233 2.

Reason for Recall

CGMP Deviations: Potential for cross contamination due to product carry over.

Distribution Pattern

Nationwide in the USA

Lot / Code Information

Lots: NE1062A, NE1062B Exp. 12/02/2022; NE1065A, NE1065B Exp. 12/13/2022; NE2011A, NE2011B Exp. 03/15/2022.

Other Recalls from Nephron Sterile Compounding Center LLC

Recall # Classification Product Date
D-0257-2025 Class II Sodium Chloride Injection 9%, USP, 500 mL, Sing... Feb 10, 2025
D-0358-2023 Class II Norepinephrine Bitartrate in 0.9% Sodium Chlori... Feb 22, 2023
D-0360-2023 Class II Phenylephrine HCl Injection, USP, 0.4 mg/10 mL ... Feb 22, 2023
D-0355-2023 Class II Diltiazem HCl in 0.7% Sodium Chloride Injection... Feb 22, 2023
D-0359-2023 Class II Phenylephrine HCl Injection, USP, 1 mg/10 mL (1... Feb 22, 2023

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.